{"entity":{"id":"immunogen","kind":"company","name":"ImmunoGen","aka":["ImmunoGen, Inc.","NASDAQ:IMGN"],"tldr":"ImmunoGen made antibody-drug conjugates, antibodies that carry a strong drug to cancer cells. Its medicine Elahere treats ovarian cancer that has stopped responding to platinum chemotherapy. AbbVie bought the company in 2024.","summary":"ImmunoGen, Inc. (formerly Nasdaq: IMGN), of Waltham, Massachusetts, developed antibody-drug conjugates. Its lead product, ELAHERE (mirvetuximab soravtansine-gynx), is a folate receptor alpha-directed ADC approved for platinum-resistant ovarian cancer. Its pipeline at the time of sale included IMGN-151, a phase 1 next-generation folate receptor alpha ADC, and pivekimab sunirine, a phase 2 CD123-directed ADC for blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer, with FDA Breakthrough Therapy designation in the relapsed or refractory setting. AbbVie agreed on 30 November 2023 to acquire ImmunoGen for USD 31.26 per share in cash, a total equity value of about USD 10.1 billion, and the merger was completed on 12 February 2024.","asOf":"2026-11-03","links":[{"label":"AbbVie to acquire ImmunoGen (8-K exhibit 99.1, 30 November 2023)","url":"https://www.sec.gov/Archives/edgar/data/855654/000110465923122415/tm2331816d2_ex99-1.htm"},{"label":"Form 8-K: completion of the merger (12 February 2024)","url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924013712/tm245856d1_8k.htm"}],"tags":[],"related":["immunome"],"cancers":["ovarian"],"sections":["adcs"],"technologies":["adc"],"targets":["folr1","cd123"],"drugs":["mirvetuximab-soravtansine","pivekimab-sunirine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["AbbVie's own record is named 'AbbVie (incl. ImmunoGen, Capstan)'; this record holds the company itself, as capstan-therapeutics does. It is not Immunome (immunome), a different company with a similar name, which is why the two are cross-linked. Completion on 12 February 2024 is from ImmunoGen's 8-K of that date. No website or founding year is recorded."],"hq":"Waltham, MA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2023,"amountUsd":10100000000,"source":"https://www.sec.gov/Archives/edgar/data/855654/000110465923122415/tm2331816d2_ex99-1.htm","note":"AbbVie's announcement of 30 November 2023, filed as exhibit 99.1 to ImmunoGen's 8-K: USD 31.26 per share in cash, total equity value of approximately USD 10.1 billion; completed 12 February 2024"}],"acquiredBy":"abbvie"},"route":"/companies/immunogen/","neighbours":{"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"immunome","kind":"company","name":"Immunome","route":"/companies/immunome/"}],"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}],"drug":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/"}]}}